Serum β2-microglobulin is frequently elevated in type 1 Gaucher patients

Tiago Koppe, Filippo Vairo, Matheus Camargo, Livia Paskulin, Liane Daudt, Ida V. Schwartz

Research output: Contribution to journalArticlepeer-review


β2-Microglobulin is the major prognostic factor in multiple myeloma, a known comorbidity of Gaucher disease. We evaluated herein serum β2-microglobulin levels of 31 type 1 Gaucher patients; for 8/31 patients, pre- and post-treatment comparisons were made. Thirteen patients (on treatment = 6) had high levels of β2-microglobulin, and showed higher chitotriosidase activity and Severity Score Index, and lower concentration of platelets, than patients with normal levels. Levels of β2-microglobulin correlated with chitotriosidase activity (ρ = 0.65; p < 0.01), platelets (ρ = - 0.42; p = 0.02) and α1- (ρ = 0.43; p = 0.02) and α2-protein bands (ρ = - 0.40; p = 0.03). Regarding pre- and post-treatment values, median β2-microglobulin levels decreased after treatment (pre- = 2931 ng/mL; post- = 1970 ng/mL; p < 0.01). Our data suggest that levels of serum β2-microglobulin are frequently elevated in type 1 Gaucher patients, correlate with severity of the disease and decrease after treatment.

Original languageEnglish (US)
Pages (from-to)38-40
Number of pages3
JournalMolecular Genetics and Metabolism Reports
StatePublished - Mar 2015


  • Biomarkers
  • Chitotriosidase
  • Gaucher disease
  • Multiple myeloma
  • Serum β-microglobulin

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Endocrinology


Dive into the research topics of 'Serum β2-microglobulin is frequently elevated in type 1 Gaucher patients'. Together they form a unique fingerprint.

Cite this